Related Experiment Video

Updated: Jun 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin

Megan D Indermaur1, Yin Xiong, Siddharth G Kamath

  • 1Department of Women's Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33629, USA.

American Journal of Obstetrics and Gynecology
|May 7, 2010
PubMed
Abstract

Insights

Genome-wide analysis identified the Src pathway as a key factor in endometrial cancer resistance to doxorubicin (DOX). Targeting this pathway enhances DOX sensitivity, offering a potential therapeutic strategy for endometrial cancer treatment.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Endometrial cancer exhibits resistance to doxorubicin (DOX), a common chemotherapeutic agent.
  • Identifying molecular mechanisms underlying DOX resistance is crucial for developing effective treatment strategies.

Purpose of the Study:

  • To identify molecular pathways contributing to endometrial cancer's resistance to doxorubicin (DOX) using genome-wide expression analysis.
  • To determine if these pathways represent viable therapeutic targets for enhancing DOX sensitivity.

Main Methods:

  • Gene expression analysis was performed on ten endometrial cancer cell lines.
  • Doxorubicin sensitivity was quantified using a cell proliferation assay (dimethylthiazoldiphenyltetrazoliumbromide).
  • Pearson's correlation identified genes associated with DOX response, followed by pathway analysis and targeted inhibition.

Main Results:

  • 2871 genes associated with DOX resistance were identified (P < .05), including components of the Src pathway.
  • Targeted inhibition of the Src pathway significantly increased DOX sensitivity in multiple endometrial cancer cell lines (RL 95-2, HEC 1B, MEF 296).

Conclusions:

  • Genome-wide expression analysis is effective in identifying therapeutic targets for endometrial cancer.
  • The Src pathway is implicated in doxorubicin resistance and serves as a potential therapeutic target to improve treatment outcomes.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...